

# Primary neuroendocrine breast carcinomas: a retrospective analysis and review of literature

Xin Yang<sup>1</sup>  
 Youde Cao<sup>2</sup>  
 Chen Chen<sup>1</sup>  
 Lin Liu<sup>1</sup>  
 Cheng Wang<sup>1</sup>  
 Shengchun Liu<sup>1</sup>

<sup>1</sup>Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University,

<sup>2</sup>Department of Pathology, Chongqing Medical University, Chongqing, People's Republic of China

**Background:** Primary neuroendocrine breast carcinomas (NEBCs) are a rare type of breast carcinomas that lack comprehensive recognition, including the clinicopathological features, therapeutic strategies, and prognostic significance. The aim of this retrospective analysis is to present and analyze our own data of primary NEBCs.

**Materials and methods:** We retrospectively reviewed the medical records from 2005 to 2015 in The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China to obtain a cohort of breast carcinoma patients who were confirmed to have primary NEBC by histopathology. The detailed clinical data along with histopathology, treatment, and follow-up aspects were gathered for analysis.

**Results:** This retrospective analysis included 19 patients with a histopathological diagnosis of primary NEBC from 2005 to 2015. Their mean age was 59.2 years (ranging from 17 to 82 years). The majority of patients (15/19) focused on stages I and II. Of the 15 patients, 14 were positive for estrogen receptor, and 11 were positive for progesterone receptor. For neuroendocrine markers, the expression rates were 8/19, 14/18, 12/14, and 2/6 for chromogranin A, synaptophysin, neuron-specific enolase, and CD56, respectively. All operable patients except the one stage M1 underwent a surgery and 4/18 had axillary lymph node metastasis. Chemotherapy was performed in 12/19, and endocrine therapy in 8/10. With a median follow-up of 59.2 months, only 2 cases progressed after postoperative systemic therapy.

**Conclusion:** The understanding of NEBC is limited due to its rarity. More evidence should be provided to enhance the understanding of NEBC, especially for diagnosis, treatment, and prognosis.

**Keywords:** primary neuroendocrine breast carcinomas, diagnosis, therapy, follow-up

## Introduction

Neuroendocrine carcinomas (NECs) are a cluster of rare and heterogeneous neoplasms, and they are widely distributed throughout the whole human body, including the stomach, intestine, pancreas, adrenal, thyroid, breast, and among other areas.<sup>1,2</sup> Most NECs occur in the gastroenteropancreatic system or respiratory tracts.<sup>3,4</sup> The primary neuroendocrine breast carcinomas (NEBCs) are reported to have a very low incidence, accounting for ~1% of all breast carcinomas.<sup>5</sup> Invasive breast carcinomas with neuroendocrine differentiation were first described by Feyrter and Hartmann in 1963;<sup>6</sup> they found that this kind of breast carcinomas showed morphological features similar to neuroendocrine tumors of the gut and lung. In 1977, Cubilla and Woodruff reported the first series of primary carcinoid of the breast including 8 patients;<sup>7</sup> this rare kind of cohort has been gradually increasingly recognized. In 2003, the World Health Organization (WHO) classification of breast tumors explicitly defined and classified NEBC; establishing that the neuroendocrine markers were detected by immunohistochemical staining in >50% of the tumor cell population, is the unique requisite for the diagnosis of NEBC.<sup>8</sup> The current 2012 WHO classification

Correspondence: Shengchun Liu  
 Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, I Youyi Road, Yuanjiagang, Yuzhong District, Chongqing 400016, People's Republic of China  
 Tel +86 23 890 184 63  
 Fax +86 23 890 111 22  
 Email liushengchun1968@163.com

of tumors subdivides NEBC into 3 groups: well-differentiated neuroendocrine tumors, poorly differentiated NECs or small cell carcinomas, and invasive breast carcinomas with neuroendocrine differentiation.<sup>9</sup> Due to the rareness of primary NEBC, most of the available knowledge was from case reports and reviews, very few were researches with small sample sizes.<sup>7,10–13</sup> In addition, a standard management of these tumors has not been established so far to date. Therefore, we present our own data about 19 NEBC patients including the clinical and pathological features, therapeutic strategies, and prognostic significance, hoping to contribute to offer more evidence for recognition of NEBC, especially for diagnosis, treatment, and prognosis.

## Patients and methods

### Patients

We retrospectively reviewed the medical records of the breast carcinoma patients who were diagnosed as breast carcinomas and had received treatment from 2005 to 2015 in The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China. Then, we allowed a series of patients confirmed to NEBC by histopathology to enroll in our analysis. Complete information of the NEBC patients, such as general information (including name, gender, age, and contact information), physical examination, imaging character, time of final diagnosis, surgical procedures, histopathology and immunohistochemistry characteristics, systemic adjuvant treatment, and follow-up outcome were collected by consulting the medical records and in consultation with the patients. This study was approved by the ethics committee from The First Affiliated Hospital of Chongqing Medical University, who deemed written informed consent not necessary due to the retrospective nature of the research.

### Diagnostic

The mammography and ultrasonography of breast were performed for further diagnosis. All lesions were diagnosed as Breast Imaging-Reporting and Data System category 5. Several cases had other imaging examinations such as magnetic resonance imaging (MRI) or positron emission tomography-computed tomography (PET-CT). However, the gold standard for diagnosing NEBC was histopathology, including the core biopsy, intraoperative frozen, and postoperative pathological examination.

### Surgical procedures

The surgical procedures included the breast-conserving surgery, the radical mastectomy, and the modified radical

mastectomy. In addition, patients were staged according to the seventh edition of the AJCC Cancer Staging Manual.<sup>14</sup>

## Immunohistochemistry

The histological slides were reviewed and classified according to the 2012 WHO classification.<sup>9</sup> Several important indexes that were correlated with breast cancer, such as estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), Ki-67 proliferation index, and oncoprotein P53, were detected by immunohistochemical staining. ER and PR were considered positive if >1% of tumor cells were stained, and HER-2 was considered positive if immunohistochemical staining was 3+. Overexpression of *HER-2* genes in fluorescent in situ hybridization (FISH) was also identified as HER-2 positive. Ki67 was identified as highly expressed if >14% tumor cells were stained. We also investigated the expression of the neuroendocrine markers by immunohistochemical staining, including chromogranin A (CgA), synaptophysin (Syn), neuron-specific enolase (NSE), and CD56. At least one mentioned neuroendocrine marker was positive in immunohistochemical staining.<sup>8</sup>

## Adjuvant therapy and follow-up

For patients enrolled in our analysis, we got their detailed treatment strategy and follow-up information by contacting them and consulting the medical records. We mainly got the information about whether they had comprehensive treatments, including operation, chemotherapy, radiotherapy, and/or endocrine therapy, and whether regular follow-up was carried out to assess the prognosis conditions.

## Results

### The clinical characteristics of all primary NEBC patients at diagnosis

From 2005 to 2015, a total of 19 NEBC patients meeting the diagnostic criteria were enrolled in our study for further analysis. All patients were women, and the median age was 61 years (ranging from 17 to 82 years, mean age 59.2 years). All patients visited our hospital due to a palpable breast mass, and then they carried out several assistant examinations for further diagnosis, such as mammography and breast ultrasonography. The lump sizes ranged from 8 to 150 mm in greatest dimension. The location appeared in the left breast in 11 patients (57.9%) and right breast in the remaining 8 patients (42.1%). They were finally diagnosed as NEBC by pathological examination. Of these patients, 18 NEBC

patients were operable and underwent operation as soon as they were confirmed; 1 patient without surgery was found to have distant metastasis at diagnosis. Among these surgery patients, only 4 of 18 patients had axillary lymph node metastasis, and the metastasis rates were 2/15, 2/16, 11/12, and 4/13, respectively. According to the pathological tumor node metastasis (pTNM) staging system of AJCC,<sup>14</sup> except for 1 patient who was unable to be staged because her breast mass was removed outside of our hospital and we failed to get her initial clinical data, 1 patient with distant metastasis at diagnosis was stage IV, 2 of 19 patients were stage III and the residual 15 patients were stage I to II (Table 1).

## The immunohistochemical of all primary NEBC patients

Except 4 patients who were unknown about the status of ER and PR, of the remaining included 15 NEBC patients, ER was expressed in 14 patients (93.3%) and PR was expressed in 11 patients (73.3%). No available data showed HER-2 was

positive in immunohistochemistry or FISH. Ki67 was highly expressed (>14%) in 4 of 10. For neuroendocrine markers, all 19 patients had detected CgA, while only 18 patients had detected Syn, 14 patients had detected NSE, and 6 patients had detected CD56. As a result, 8 of 19 (42.1%) were CgA positive, 14 of 18 (77.8%) were Syn positive, 12 of 14 (85.7%) were NSE positive, and 2 of 6 (33.3%) were CD56 positive, as listed in Table 2.

## Adjuvant therapy

For 18 operable patients, only 1 case with local advanced disease received neoadjuvant chemotherapy in order to reduce the lesions' size and remove all lesions successfully, so that they could get a long-term local control (Table 3). The one stage M1 also received neoadjuvant chemotherapy. In addition, apart from 2 patients without information of post-operative therapy, 11 patients had undergone postoperative chemotherapy, while 5 patients older than 75 years did not receive chemotherapy on account of they were so old that

**Table 1** The clinical information of primary NEBC patients at diagnosis

Number	Gender	Age (years)	Location	Diagnosis date, month/year	Single/multiple lesions	Tumor size (mm)	Surgical treatment	Lymph node (LN)	Stage
1	Female	61	Left	01/2015	Single	14	MRA + SLNB + ALND	2/15	II
2	Female	77	Left	08/2015	Single	15	MRA + ALND	0/11	I
3	Female	17	Left	06/2014	Multiple (2)	33 and 18	No	Bilateral neck, left supraclavicular and mediastinum LN, pleura	IV
4	Female	57	Left	03/2014	Single	35	Mastectomy + SLNB	0/1	II
5	Female	64	Left	03/2012	Single	16	MRA + ALND	0/13	I
6	Female	65	Left	11/2011	Single	24	MRA + ALND	0/18	II
7	Female	45	Left	11/2011	Single	8	MRA + ALND	0/14	I
8	Female	46	Right	05/2011	Single	31	MRA + ALND	2/16	II
9	Female	43	Right	10/2006	Single	30	MRA + ALND	0/8	II
10	Female	58	Right	04/2009	Single	24	MRA + ALND subcutaneous	11/12	III
11	Female	41	Right	03/2010	Multiple (3)	Max: 10	Mastectomy + ALND + breast reconstruction	4/13	II
12	Female	79	Left	12/2009	Single	20	MRA + ALND	0/11	I
13	Female	82	Right	07/2008	Single	130 (with ulceration)	Mastectomy	0/2	III
14	Female	53	Left	11/2007	Single	75	MRA + ALND	0/17	II
15	Female	69	Right	05/2007	Single	15	MRA + ALND	0/30	I
16	Female	77	Left	03/2008	Single	45	MRA + ALND	0/17	II
17	Female	50	Right	06/2005	Single	15	MRA + ALND	0/13	I
18	Female	65	Right	07/2005	Single	Unknown	MRA + ALND	0/17	Unknown
19	Female	76	Left	12/2005	Single	50	MRA + ALND	0/13	II

**Abbreviations:** NEBC, neuroendocrine breast carcinoma; MRA, modified radical mastectomy; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection.

**Table 2** The immunohistochemistry of primary NEBC patients

Number	ER	PR	HER-2/FISH	CgA	Syn	NSE	CD56	Ki67 (%)	P53 (%)
1	P	N	(2+)/N	N	P	P	N	20	<5
2	P	P	N	P	P	N	N	5	N
3	N	N	None	N	P	None	P	80	P
4	P	P	N	P	P	None	N	3	N
5	P	P	N	N	N	P	None	<5	P
6	P	P	(2+)/N	N	P	P	None	80	50
7	P	P	(2+)/N	N	N	P	None	<3	P
8	P	P	N	N	P	P	None	50	5
9	P	P	N	P	P	None	None	None	N
10	P	N	N	P	P	None	N	None	N
11	P	P	N	P	N	P	None	10	5
12	P	P	N	N	P	P	None	5	N
13	None	None	None	P	P	N	None	None	None
14	P	P	(2+)/none	N	P	P	None	None	N
15	P	P	N	P	P	P	P	None	N
16	None	None	None	P	P	None	None	None	None
17	None	None	None	N	None	P	None	None	None
18	P	N	N	N	N	P	None	None	N
19	None	None	None	N	P	P	None	None	None

**Abbreviations:** NEBC, neuroendocrine breast carcinoma; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2; FISH, fluorescent in situ hybridization; CgA, chromogranin A; Syn, synaptophysin; NSE, neuron-specific enolase; P, positive; N, negative.

they were difficult to endure postoperative chemotherapy. However, within these 11 patients who received postoperative chemotherapy, 2 patients did not finish the entire planned chemotherapy because of the unbearable adverse reaction. The specific chemotherapy program of every patient is listed in Table 3.

For radiotherapy, only 3 of 19 patients were recommended; 1 of them was a young patient with multiple lesions and distant metastasis, 2 other patients were middle-aged women with >3 lymph node metastasis, but we failed to collect radiotherapy data of one of them because we did not contact the patient (Table 3).

**Table 3** The adjuvant therapy and clinical follow-up of primary NEBC patients

Number	Neoadjuvant chemotherapy	Chemotherapy	Radiotherapy	Endocrine therapy	Follow-up (months)	Recurrence and metastasis	Survival
1	No	Yes, EC-T	Not required	No	15.5	No	Yes
2	No	No	Not required	Yes, exemestane	16.4	No	Yes
3	Yes, EP	No	Yes	Not required	22.9	Yes, bilateral neck, left supraclavicular and mediastinum LN, pleura	Yes
4	No	Yes, TEC*	Not required	Yes, letrozole	25.3	No	Yes
5	No	Yes, TC	Not required	Yes, anastrozole	49.5	No	Yes
6	No	Yes, TEC*	Not required	Yes, anastrozole	53.6	No	Yes
7	No	Yes, TEC	Not required	Yes, tamoxifen	53.9	No	Yes
8	No	Yes, TT#C	Not required	Yes, exemestane	59.4	No	Yes
9	No	Yes, TP	Not required	Yes, tamoxifen	114	Yes, brain	Yes
10	Yes, TAC	Yes, TAC	Yes	Yes, anastrozole	85	Yes, bone and liver	Yes
11	No	Yes, TEC	Unknown	Unknown	73.4	Unknown	Unknown
12	No	No	Not required	No	57.7	No	Death
13	No	No	Not required	Unknown	52.4	No	Death
14	No	Yes, CEF	Not required	Unknown	101.5	Unknown	Unknown
15	No	Yes, CT#F	Not required	Unknown	107.3	Unknown	Unknown
16	No	No	Not required	Unknown	Unknown	Unknown	Unknown
17	No	Unknown	Not required	Unknown	Unknown	Unknown	Unknown
18	No	Unknown	Not required	Unknown	Unknown	Unknown	Unknown
19	No	No	Not required	Unknown	Unknown	Unknown	Unknown

**Notes:** T#: pirarubicin (THP). \*Not finished entire planned chemotherapy.

**Abbreviations:** NEBC, neuroendocrine breast carcinoma; E, epirubicin; C, cyclophosphamide; T, docetaxel; F, fluorouracil (5-Fu); P, cis-platinum; LN, lymph node.

By consulting the medical record and asking patients, we found that only 8 women received endocrine therapy and the selection of medicines depended on their menstrual status. In total, 1 patient was negative in hormone receptor and did not require endocrine therapy and 2 patients refused to receive endocrine therapy. The other 8 patients had no available endocrine therapy data (Table 3).

## Post-therapy surveillance and follow-up

With a median follow-up of 59.2 months (ranging from 15.5 to 114), 2 of the patients died due to nonbreast cancer causes, 7 patients were lost to follow-up, and the remaining 10 patients were still alive. Of the 10 alive women, 7 survived without recurrence and metastasis, 1 of 10 was staged M1 at the preliminary diagnosis, and only 2 of 10 cases progressed after systemic therapy.

One patient was a 58-year-old woman with disease of the right breast, and 11/12 confirmed axillary lymph node metastasis by surgery. She was readmitted to our hospital due to the abnormal central nervous system symptoms. The PET-CT scan recognized isolated occupied lesions at her left frontal lobe, without other suspicious lesions. Given her NEBC history that she was diagnosed before 3.6 years, she was highly suspected of brain metastases and received an operation to remove the intracranial tumor. Eventually, the postoperative pathological examination confirmed to be the metastatic NEC. After the operation, she has continued to take the medication of anastrozole, up to now, without new suspicious lesions.

Another patient was a 43-year-old woman who developed bone and hepatic metastases during the follow-up. Initially, she underwent a modified radical mastectomy with axillary lymph node dissection and a complete postoperative adjuvant chemotherapy. Subsequently, the patient continued with endocrine therapy until the ilium bone metastases were detected after a follow-up of 32 months. No evidence of additional suspicious lesion in the whole body was noted by PET-CT. The patient carried out 6 cycles of chemotherapy and local radiotherapy of the ilium, as well as diphosphonate for 1 year. Meanwhile, the endocrine therapy was continued. Unfortunately, over a period of 38 months, after she was confirmed as NEBC for 70 months, she undertook a spiral computed tomography (CT) of the abdomen (Figure 1), and the result revealed that the density of liver parenchyma was diffusely reduced, with extensive round-like higher density lesions in plain scan and multiple nodular enhancement in enhanced CT of the liver. Meanwhile, the blood tumor marker carcinoembryonic antigen (CEA) of this patient was significantly increased. A lot of evidence tended toward

the diagnosis of hepatic metastases. For further treatment, an operation of ovarian ablation followed by anastrozole therapy was performed for her progressive disease, combined with capecitabine. After 7 months (in April 2013), the CT of the abdomen showed that the hepatic lesions noteworthy decreased (Figure 2), as well as the level of CEA due to the effect of anastrozole and capecitabine therapy, and hence, the therapy was continued. The reinspection of CT of the abdomen and circulating CEA in May 2014 suggested an improvement of the patient's disease (Figure 3). However, in October 2014, the patient was readmitted to our hospital because of advance of the bone and hepatic metastatic lesions (Figure 4A and B) and increase in the CEA. As a result, the patient received chemotherapy again, and the hepatic lesions had obviously narrowed after chemotherapy (Figure 4C and D). Later, capecitabine was used as maintenance therapy, and the disease in bone and liver has been stable so far.


## Discussion

Primary NEBCs are an uncommon entity, and were first described by Feyrter and Hartmann in 1963.<sup>6</sup> In spite of several sporadic reports, not until 2003 when the WHO defined and classified it, did the public have a real sense of recognition of NEBC. However, enhanced attention was paid to NEBC over the past few years; there were still some challenges in the management of NEBC, including the diagnosis, treatments, and long-term outcome.

Imaging examination such as mammography, ultrasonography, or MRI could provide some helpful imaging findings, but there was still a degree of difficulty in the diagnosis of NEBC by imaging examination; a number of NEBC patients appeared to have signs of common breast carcinomas such as ill-defined margins, irregular shapes, calcification, and so on, and other patients' breast carcinomas might show regular shapes and well-circumscribed margins just like benign lesions.<sup>15,16</sup> As previously reported, the imaging characteristics of NEBC in our study were also variable on radiography (Tables S1 and S2), but the majority of NEBC tended to present poor features in mammography or ultrasonography.

It is widely accepted that pathological examinations are gold standards for the diagnosis of carcinomas. Microscopically, the tumor cells in well-differentiated neuroendocrine tumors might present spindle and plasmacytoid appearances, occasionally with clear cell features, while the tumor cells in poorly differentiated NECs and small cell carcinomas might appear with high nuclear/cytoplasmic ratios, an active mitotic rate, smoky dense chromatin, areas of necrosis, and frequent lymphovascular emboli.<sup>9,17</sup> However, primary






**Figure 1** CT image of the patient with hepatic metastasis in September 2012, 70 months after the initial surgical treatment.

**Notes:** (A and B) The image of plain scan showed that the density of liver parenchyma was diffusely reduced, and extensive round-like higher density lesions in the liver. (C and D) Enhanced CT revealed multiple nodular enhancement in liver.

**Abbreviation:** CT, computed tomography.

NEBCs were not easily recognized initially just depend on routine microscopic morphology and immunohistochemistry features due to mixed growth patterns.<sup>13</sup> Although the WHO Working Group defined NEBC as a unique cohort that showed morphological features similar to neuroendocrine tumors of the gastrointestinal tract and lung,<sup>8</sup> a number of studies reported that some nonspecial or special breast carcinomas also presented neuroendocrine differentiation.<sup>18–20</sup> Furthermore, the 2012 WHO Working Group acknowledged that this 50% cut-off, which was a requirement in 2003, was conceptually arbitrary and reached an agreement on incorporating this group in NEBC without the requirement for expression of neuroendocrine markers in at least 50% of tumor cell population.<sup>9</sup> Therefore, the current classification of NEBC is well-differentiated neuroendocrine tumors, poorly differentiated NECs or small cell carcinomas, and invasive

breast carcinomas with neuroendocrine differentiation. This makes more challenging the diagnosis of NEBC especially for invasive breast carcinomas with neuroendocrine differentiation, and it suggests that particularly immunohistochemical staining for neuroendocrine markers including CgA, Syn, NSE, and CD56 is necessary for recognizing this infrequent type of breast carcinomas.<sup>5,21</sup> In agreement with earlier studies, NEBC tended to present hormone receptors (ER and/or PR) and absent HER-2.<sup>5,22,23</sup> However, positivity of ER and/or PR alone was not sufficient to confirm primary NEBC because the hormone receptors were not exclusive to the mammary gland.<sup>24,25</sup> In the diagnosis of primary NEBC, metastasis NECs presenting as a breast lump should be excluded and an in situ component and/or positive immunohistochemical reactivity for CK7 and mammaglobin support a primary breast origin.<sup>24,26–28</sup>



**Figure 2** Post-therapy abdominal CT of the patient with hepatic metastasis in April 2013.


**Note:** Over a period of 7 months of treatment, both (A and B) plain scan and (C and D) enhanced CT showed that the hepatic lesions were gradually decreased.

**Abbreviation:** CT, computed tomography.

Primary NEBCs were reported to be more common in elderly women.<sup>5,10,29,30</sup> In our study, the age of NEBC patients ranged from 17 to 82 years, and the mean age was 59.2 years, which was in accordance with previous reports. All operable patients except the one who was stage M1 received surgery, and the benefits were obvious. Given still lack of a standard treatment protocol for this kind of uncommon carcinomas, current treatment protocol of primary NEBC was similar to that of invasive breast carcinomas.<sup>10,12,22,29</sup> Surgery resection should always be considered as the first line of treatment. Endocrine therapy had been proved to be crucial to the hormone receptor-positive breast tumors, however, whether there was equally important effect of endocrine therapy for NEBC coming from a different origin, especially for NEBC patients with high expression of hormone receptor, was yet to reach a consensus. But several reports presented that these adjuvant systemic treatments including chemotherapy,

radiotherapy, and endocrine therapy might play an important role and should be performed according to individuality of the patients with NEBC.<sup>31,32</sup> Moreover, several publications reported that somatostatin and its analogs might be of help for primary NEBC with scintigraphic-confirmed somatostatin-receptor expression.<sup>23,33</sup> But in our study, none of the patients received treatment of somatostatin and its analogs.

The prognosis of primary NEBC was equally inconsistent. Primary NEBCs were reported to be associated with worse long-term outcomes compared to primary invasive breast carcinomas.<sup>12</sup> Similarly, a population-based study from the Surveillance, Epidemiology, and End Results (SEER) database showed that NEBCs were an aggressive breast carcinoma type with significantly shorter overall survival (OS) and disease-specific survival (DSS) than nonspecial invasive breast carcinoma.<sup>30</sup> To the contrary, few studies demonstrated a better prognosis in NEBC patients.<sup>21,34,35</sup>



**Figure 3** Post-therapy abdominal CT of the patient with hepatic metastasis in May 2014.

**Note:** With 20 months of treatment, the hepatic lesions were further reduced in both (A and B) plain scan and (C and D) enhanced CT.

**Abbreviation:** CT, computed tomography.

There was also some studies that showed no difference from other breast carcinomas with regard to prognosis and clinical presentation.<sup>36,37</sup> Within our study, the number of patients with NEBC were too few to make a valuable survival analysis. However, for our included 10 patients with available clinical follow-up data, 70% patients were alive free of disease and 30% are alive well with tumor, which presents a better prognosis in accordance with previous reports. Besides, two patients with disease progression after initial treatment still obtained a good effect in metastasis diseases, and they all alive without further progression of the disease. The outstanding treatment effects of these 2 patients might prove a well prognosis for NEBC patients even if they had distant metastasis. It could also provide more experience in this unusual disease.


It is also undeniable that there are a few limitations in our study. On the one hand, we could not collect sufficient

number of patients because of a lack of NEBC. On the other hand, some patients were lost to follow-up and some patients had poor treatment compliance, which led us to obtain fewer available data. Hence, we could not make a significant conclusion.

## Conclusion

NEBCs are a rare type of breast carcinomas and tend to occur in older women. They are more likely to be ER/PR positive and HER-2 negative. Particularly, immunohistochemical staining for neuroendocrine markers was extremely contributed to the confirmation of this uncommon cohort. The recognition of NEBC is limited, and the current treatment protocol is similar to general invasive breast carcinomas. Previous studies are still ambiguous with regard to the therapeutic regimen and long-term outcome. Our study retrospectively reviewed related literature and our own clinical





**Figure 4** Surveillance CT.

**Notes:** (A and B) The CT of the abdomen showed that the hepatic metastasis lesions of this patient progressed again in October 2014. (C and D) After a modified therapy, the reduction of hepatic lesions was obviously found by CT of the abdomen in February 2015.

**Abbreviation:** CT, computed tomography.

information and summarized clinical features, therapeutic strategies, and prognostic significance of NEBC, which might be helpful to increase knowledge of NEBC. However, more evidence should be provided to enhance the understanding of diagnosis, treatment, and prognosis for NEBC.

## Acknowledgments

This work was supported in part by the Pathology Department of Chongqing Medical University and the medical records and statistics room of the First Affiliated Hospital of Chongqing Medical University. Thanks for their data support. This work was also supported by grants from the National Natural Science Foundation of China (NSFC, 81272265 and 81472658, URL: <http://www.nsfc.gov.cn/>). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## Disclosure

The authors report no conflicts of interest in this work.

## References

1. Solcia E, Kloppel G, Sobin LH. World Health Organization international histological classification of tumours: histological typing of endocrine tumours: second edition. *Clin Endocrinol*. 2000;53(2):259–259.
2. Hauser H, Wolf G, Uranus S, Klimpfinger M. Neuroendocrine tumours in various organ systems in a ten-year period. *Eur J Surg Oncol*. 1995;21(3):297–300.
3. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. *Cancer*. 2003;97(4):934–959.
4. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. *Lancet Oncol*. 2008;9(1):61–72.
5. Lopez-Bonet E, Alonso-Ruano M, Barraza G, Vazquez-Martin A, Bernado L, Menendez JA. Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling. *Oncol Rep*. 2008;20(6):1369–1374.
6. Feyrter F, Hartmann G. On the carcinoid growth form of the carcinoma mammae, especially the carcinoma solidum (gelatinosum) mammae. *Frankf Z Pathol*. 1963;73:24–39.

7. Cubilla AL, Woodruff JM. Primary carcinoid tumor of the breast: a report of eight patients. *Am J Surg Pathol*. 1977;1(4):283–292.
8. Tavassoli FA, Deyilee P. *Tumors of the Breast and Female Genital Organ: Pathology and Genetics*. Lyon: IARC Press; 2003.
9. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, editors. *World Health Organization Classification of Tumours of the Breast*. 4th ed. Lyon: IARC Press; 2012.
10. Papotti M, Macri L, Finzi G, Capella C, Eusebi V, Bussolati G. Neuroendocrine differentiation in carcinomas of the breast: a study of 51 cases. *Semin Diagn Pathol*. 1989;6(2):174–188.
11. Rovera F, Masciocchi P, Coglitore A, et al. Neuroendocrine carcinomas of the breast. *Int J Surg*. 2008;6(suppl 1):S113–S115.
12. Wei B, Ding T, Xing Y, et al. Invasive neuroendocrine carcinoma of the breast: a distinctive subtype of aggressive mammary carcinoma. *Cancer*. 2010;116(19):4463–4473.
13. Tang F, Wei B, Tian Z, et al. Invasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges. *Histopathology*. 2011;59(1):106–115.
14. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. *AJCC Cancer Staging Manual*. 7th ed. New York, NY: Springer; 2010.
15. Gunhan-Bilgen I, Zekioglu O, Ustun EE, Memis A, Erhan Y. Neuroendocrine differentiated breast carcinoma: imaging features correlated with clinical and histopathological findings. *Eur Radiol*. 2003;13(4):788–793.
16. Jeon CH, Kim SM, Jang M, et al. Clinical and radiologic features of neuroendocrine breast carcinomas. *J Ultrasound Med*. 2014;33(8):1511–1518.
17. Tan PH, Schnitt SJ, van de Vijver MJ, Ellis IO, Lakhani SR. Papillary and neuroendocrine breast lesions: the WHO stance. *Histopathology*. 2015;66(6):761–770.
18. Kwon SY, Bae YK, Gu MJ, et al. Neuroendocrine differentiation correlates with hormone receptor expression and decreased survival in patients with invasive breast carcinoma. *Histopathology*. 2014;64(5):647–659.
19. Ishida M, Umeda T, Abe H, Tani T, Okabe H. Neuroendocrine carcinoma of the breast with a mucinous carcinoma component: a case report with review of the literature. *Oncol Lett*. 2012;4(1):29–32.
20. Tanaka N, Katayama K, Negishi T, Kano H, Uchida N, Kuwano H. Case of breast cancer with endocrine differentiation. *Int Surg*. 2007;92(4):214–217.
21. Makretsov N, Gilks CB, Coldman AJ, Hayes M, Huntsman D. Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. *Hum Pathol*. 2003;34(10):1001–1008.
22. Rovera F, Lavazza M, La Rosa S, et al. Neuroendocrine breast cancer: retrospective analysis of 96 patients and review of literature. *Int J Surg*. 2013;11(suppl 1):S79–S83.
23. Adams RW, Dyson P, Barthelmes L. Neuroendocrine breast tumours: breast cancer or neuroendocrine cancer presenting in the breast? *Breast*. 2014;23(2):120–127.
24. Richter-Ehrenstein C, Arndt J, Buckendahl AC, et al. Solid neuroendocrine carcinomas of the breast: metastases or primary tumors? *Breast Cancer Res Treat*. 2010;124(2):413–417.
25. Sica G, Wagner PL, Altorki N, et al. Immunohistochemical expression of estrogen and progesterone receptors in primary pulmonary neuroendocrine tumors. *Arch Pathol Lab Med*. 2008;132(12):1889–1895.
26. Perry KD, Reynolds C, Rosen DG, et al. Metastatic neuroendocrine tumour in the breast: a potential mimic of in-situ and invasive mammary carcinoma. *Histopathology*. 2011;59(4):619–630.
27. Christie M, Chin-Lenn L, Watts MM, Tsui AE, Buchanan MR. Primary small cell carcinoma of the breast with TTF-1 and neuroendocrine marker expressing carcinoma in situ. *Int J Clin Exp Pathol*. 2010;3(6):629–633.
28. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. *Mod Pathol*. 2000;13(9):962–972.
29. Cloyd JM, Yang RL, Allison KH, Norton JA, Hernandez-Boussard T, Wapnir IL. Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma of the breast. *Breast Cancer Res Treat*. 2014;148(3):637–644.
30. Wang J, Wei B, Albarracín CT, Hu J, Abraham SC, Wu Y. Invasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database. *BMC Cancer*. 2014;14:147.
31. Yildirim Y, Elagoz S, Koyuncu A, Aydin C, Karadayi K. Management of neuroendocrine carcinomas of the breast: a rare entity. *Oncol Lett*. 2011;2(5):887–890.
32. Berruti A, Saini A, Leonardo E, Cappia S, Borasio P, Dogliotti L. Management of neuroendocrine differentiated breast carcinoma. *Breast*. 2004;13(6):527–529.
33. Saeed A, Rehman A, Zaidi SA, Shaukat T, Jamil K, Abdullah K. Neuroendocrine carcinoma of breast. *J Coll Physicians Surg Pak*. 2011;21(6):371–373.
34. Tse GM, Ma TK, Chu WC, Lam WW, Poon CS, Chan WC. Neuroendocrine differentiation in pure type mammary mucinous carcinoma is associated with favorable histologic and immunohistochemical parameters. *Mod Pathol*. 2004;17(5):568–572.
35. Zekioglu O, Erhan Y, Ciris M, Bayramoglu H. Neuroendocrine differentiated carcinomas of the breast: a distinct entity. *Breast*. 2003;12(4):251–257.
36. Sapino A, Papotti M, Righi L, Cassoni P, Chiusa L, Bussolati G. Clinical significance of neuroendocrine carcinoma of the breast. *Ann Oncol*. 2001;12(suppl 2):S115–S117.
37. Miremadi A, Pinder SE, Lee AH, et al. Neuroendocrine differentiation and prognosis in breast adenocarcinoma. *Histopathology*. 2002;40(3):215–222.

## Supplementary materials

**Table S1** Mammography features of NEBC

Number	Presentation	Location	Shape	Margins	Density	Calcification	BI-RADS
1	Mass	LUOQ	Round	Indistinct	High	Clustered	4C
2	Mass	LUOQ	Round	Indistinct	High	None	4B
3	Mass	LLOQ	Oval	Well defined	High	None	0
4	Mass	LUIQ	Oval	Well defined	High	None	4B
5	Nondetectable						0
6	Mass	LLOQ	Irregular	Circumscribed	High	Micro	4A
7	Mass	LU	Irregular	Indistinct	High	Micro	4C
8	Nondetectable						
9	Unknown						
10	Distortion	RUOQ	Not obvious	Indistinct	Isodensity	Needle like	5
11	Calcification	RUOQ	Not obvious	Not obvious	High	Sand like	6
12	Mass	LUOQ	Irregular	Spiculate	High	None	5
13	Not done						
14	Mass	LUOQ	Irregular	Indistinct	High	Sand like	Unknown
15	Mass	RUOQ	Lobulated	Spiculate	High	None	6

**Abbreviations:** NEBC, neuroendocrine breast carcinoma; BI-RADS, Breast Imaging-Reporting and Data System; LUOQ, left upper outer quadrant; LLOQ, left lower outer quadrant; LUIQ, left upper inner quadrant; LU, left upper; RUOQ, right upper outer quadrant.

**Table S2** Ultrasonography features of NEBC

Number	Shape	Margins	Echogenicity	Calcification	Color Doppler	Lymph node enlargement
1	Round	Indistinct	Hypoechoic	Punctiform	Increased blood supply	Yes
2	Round	Indistinct	Hypoechoic	None	None	No
3	Oval	Well defined	Hypoechoic	None	High-velocity blood flow	Yes
4	Oval	Well defined	Hypoechoic	None	High-velocity blood flow	Yes
5	Irregular	Indistinct	Hypoechoic	None	None	No
6	Irregular	Indistinct	Heterogeneous	None	Increased blood supply	Yes
7	Irregular	Spiculate	Heterogeneous	None	None	No
8	Irregular	Crab like	Heterogeneous	None	Increased blood supply	No
9	Unknown					
10	Lobulated	Indistinct	Heterogeneous	Clustered	Increased blood supply	Yes
11	Oval	Indistinct	Heterogeneous	None	None	Yes
12	Irregular	Indistinct	Heterogeneous	Punctiform	Increased blood supply	Yes
13	Not done					
14	Irregular	Crab like	Heterogeneous	None	Increased blood supply	No
15	Irregular	Crab like	Heterogeneous	Punctiform	Increased blood supply	No

**Abbreviation:** NEBC, neuroendocrine breast carcinoma.

### OncoTargets and Therapy

### Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on

Submit your manuscript here: <http://www.dovepress.com/oncotargets-and-therapy-journal>

patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Dovepress